New data for AREXVY, GSK’s respiratory syncytial virus vaccine, …
Indication for AREXVY. AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 60 years of age and older; Individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV. Important Safety Information for ...
Arexvy Looks Promising for RSV Protection in Younger At-Risk …
Nov 4, 2024 · Arexvy is currently approved for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for LRTD caused by RSV. The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV ...
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, …
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions and in adults who are immunocompromised.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
The FDA has approved Arexvy, the first RSV vaccine approved for use in the U.S. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of...
GSK presents positive data for AREXVY, its respiratory syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain underlying medical conditions.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
May 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, …
Oct 24, 2024 · New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease. Single dose of vaccine elicited robust...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain underlying medical...
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, …
PHILADELPHIA, October 24, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49...